IRUS Total

The utility of biomarkers in hepatocellular carcinoma: review of urine-based 1H-NMR studies – what the clinician needs to know

File Description SizeFormat 
IJGM-150312-the-utility-of-biomarkers-in-hcc--review-of-urine-based-nmr-_112417.pdfPublished version1.9 MBAdobe PDFView/Open
Title: The utility of biomarkers in hepatocellular carcinoma: review of urine-based 1H-NMR studies – what the clinician needs to know
Authors: Cartlidge, C
Alkhatib, A
Taylor-Robinson, SD
Item Type: Journal Article
Abstract: Hepatocellular carcinoma (HCC) is the fifth most common malignancy, the third most common cause of cancer death, and the most common primary liver cancer. Overall, there is a need for more reliable biomarkers for HCC, as those currently available lack sensitivity and specificity. For example, the current gold-standard biomarker, serum alpha-fetoprotein, has a sensitivity of roughly only 70%. Cancer cells have different characteristic metabolic signatures in biofluids, compared to healthy cells; therefore, metabolite analysis in blood or urine should lead to the detection of suitable candidates for the detection of HCC. With the advent of metabonomics, this has increased the potential for new biomarker discovery. In this article, we look at approaches used to identify biomarkers of HCC using proton nuclear magnetic resonance (1H-NMR) spectroscopy of urine samples. The various multivariate statistical analysis techniques used are explained, and the process of biomarker identification is discussed, with a view to simplifying the knowledge base for the average clinician.
Issue Date: 27-Nov-2017
Date of Acceptance: 22-Sep-2017
URI: http://hdl.handle.net/10044/1/51198
DOI: https://dx.doi.org/10.2147/IJGM.S150312
ISSN: 1178-7074
Publisher: Dove Medical Press
Start Page: 431
End Page: 442
Journal / Book Title: International Journal of General Medicine
Volume: 2017
Issue: 10
Copyright Statement: This work is published by Dove Medical Press Limited, and licensed under a Creative Commons Attribution License. The full terms of the License are available at http://creativecommons.org/licenses/by/4.0/. The license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Sponsor/Funder: Wellcome Trust
Wellcome Trust
Funder's Grant Number: 097816/Z/11/ZR
Keywords: 1103 Clinical Sciences
Publication Status: Published
Appears in Collections:Department of Surgery and Cancer